
GSK wins FDA approval for lung cancer drug
Key points
- The US FDA granted accelerated approval to Nelkarmi, GSK's targeted treatment for advanced ALK-positive non-small cell lung cancer.
- The approval expands GSK's oncology portfolio, providing another treatment option for patients whose cancer has progressed after existing ALK inhibitor therapies.
- The drug came through GSK's $10.6 billion Nuvalent acquisition, completed in July 2026, which also delivered another FDA-approved lung cancer treatment, Jideytro.
GSK (NYSE:GSK) secured US FDA accelerated approval for neladalkib, branded Nelkarmi, to treat adults with advanced ALK-positive non-small cell lung cancer whose disease has progressed after treatment with ALK inhibitors.
The approval provides another targeted treatment option for patients whose cancer has progressed despite existing ALK therapies, for whom chemotherapy has often been the remaining treatment option.
Neladalkib belongs to a class of medicines called ALK tyrosine kinase inhibitors, which block abnormal proteins that drive cancer cell growth.
The FDA's accelerated approval pathway allows certain medicines to reach patients earlier based on preliminary evidence, while requiring confirmatory studies to verify their clinical benefits.
GSK completed its approximately $10.6 billion acquisition of Nuvalent in July 2026, gaining neladalkib, the ROS1-targeted drug zidesamtinib and an experimental HER2 inhibitor as part of the transaction.
The acquisition supports GSK's return to oncology after exiting the business about a decade ago, while its other acquired lung cancer treatment, Jideytro, received FDA approval on July 22, 2026, for previously treated ROS1-positive non-small cell lung cancer.
Frequently asked questions
More from United States
Boxlight revenue advances 2.5% to $30.1 million
Algorhythm sales rise 20% as net loss widens to $17.8 million
Elbit Systems revenue rises 17.2% to $2.25 billion
UL Solutions agrees $350 million Worldly deal
Disney revenue reaches $25.9 billion as profit rises
Viking Q3 revenue climbs 9.2% year over year to $2.18B


_1417563_640x360_2503007299812-640x360.webp&w=3840&q=75)
